secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0001493152-25-004880
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal
--------------------------------------------------------------------------------

- Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.
- Ensysce issues 1% of outstanding shares as restricted stock vesting in thirds based on project milestones.
- Development costs compensated with 50% restricted stock and 50% freely tradeable shares at 1.2x actual cost.
- 15-year term with IP created related to Ensysce's products owned exclusively by Ensysce.
- Share price fixed using trailing five-day closing price; no future variable pricing permitted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/0001493152-25-004880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-004880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer